MSME (Udyam registered) Ministry of MSME
- Category
- Small (2023-24)
- Udyam number
- UDYAM-TS-20-0012350
Daewoong Pharmaceutical (India) Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹4.87 Cr
▼ 40% YoY
Net loss · FY 2025
₹3.28 Cr
Net margin -67.4%
EBITDA · FY 2025
-₹2.39 Cr
EBITDA margin -49.1%
Authorised capital
₹2.9 Cr
Registered with MCA
Paid-up capital
₹2.86 Cr
Issued & subscribed
Company age
14 yrs
Est. 2012
Employees · EPFO
23
Provident fund records
Directors on board
3
As per MCA filings
About Daewoong Pharmaceutical (India) Private Limited
Data last updated:
Daewoong Pharmaceutical (India) Private Limited is a foreign private limited company based in Hyderabad, Telangana, India, a subsidiary of Aewoong Pharmaceutical Co.Ltd. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 30 November 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2012FTC084511. Its GSTIN is 36AAECD4700D1Z7 (Telangana). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹2.9 Cr and a paid-up capital of ₹2.86 Cr. It is led by directors including Gwan Young Kim and Chung Hyun Song.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No.5A A.P.I.I.C Kukatpally, Hyderabad, Telangana, India – 500072.
As per the financials filed for FY 2025, the company reported a revenue of ₹4.87 Cr, a decline of 40% compared to the previous year. For the same year it recorded a net loss of ₹3.28 Cr (net margin -67.4%) and EBITDA of -₹2.39 Cr (EBITDA margin -49.1%). Revenue has declined at a compounded annual rate (CAGR) of 15% over three years and 3% over five years.
The company has about 23 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Daewoong Pharmaceutical. The company has 2 deals on record (1 rights issue, 1 funding round), with disclosed funding of ₹2.21 Cr; the latest was in March 2019.
Daewoong Pharmaceutical (India) Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-20-0012350). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website daewoong.com.
Company details
CIN U24232TG2012FTC084511
Registration Number 084511
Incorporation Date 30 November 2012
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Aewoong Pharmaceutical Co.Ltd
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-TS-20-0012350
CIN history
Daewoong Pharmaceutical (India) has one previous CIN (Corporate Identification Number): U24232AP2012FTC084511. The current CIN is U24232TG2012FTC084511, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2012FTC084511 | Current |
| U24232AP2012FTC084511 | Previous |
Key People
Neelima Aryasomayajula Additional Director Gwan Young Kim Director Chung Hyun Song Director Recognitions & Rankings of Daewoong Pharmaceutical (India)
Contact details
Daewoong Pharmaceutical (India) Private Limited's registered office is in Hyderabad, Telangana. Its website is daewoong.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressPlot No.5A A.P.I.I.C Kukatpally, Hyderabad, Telangana, India – 500072
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Daewoong Pharmaceutical (India) Private Limited, buy the company report.
Comprehensive company report
Daewoong Pharmaceutical (India) Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Daewoong Pharmaceutical (India) operates one associated brand: Daewoong Pharmaceutical. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Therapies for gastrointestinal disorders and related diseases are developed. | daewoong.com |
Business activity
The main business activity of Daewoong Pharmaceutical (India) is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Daewoong Pharmaceutical (India) Private Limited, buy the company report.
Financials of Daewoong Pharmaceutical (India) Private Limited
FY 2025 filings availableDaewoong Pharmaceutical (India) Private Limited reported revenue of ₹4.87 Cr (down 40% YoY) for FY 2025.
Revenue · FY 2025
₹4.87 Cr ▼ 40%
Net loss · FY 2025
₹3.28 Cr margin -67.4%
EBITDA · FY 2025
-₹2.39 Cr margin -49.1%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 40%
3 years · compounded
▼ 15%
5 years · compounded
▼ 3%
EBITDA CAGR growth
1 year
▼ 208%
3 years · compounded
▼ 55%
5 years · compounded
▼ 35%
Revenue has declined at a compounded annual rate (CAGR) of 3% over five years, including a 40% fall in the latest year. EBITDA fell 208% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹2.39 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹3.28 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -49.1% | ||||
| Net Profit Margin | -67.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Daewoong Pharmaceutical (India) Private Limited, buy the company report.
Board of directors of Daewoong Pharmaceutical (India) Private Limited
Daewoong Pharmaceutical (India) has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Neelima Aryasomayajula | Additional Director | 21 May 2024 | 2 Years 5 Months | Current |
| Gwan Young Kim | Director | 09 Apr 2018 | 8 Years 6 Months | Current |
| Chung Hyun Song Also directs: CG Medtech India Private Limited | Director | 08 Feb 2016 | 10 Years 8 Months | Current |
Auditor
Daewoong Pharmaceutical (India) Private Limited is audited by RAMANATHAM & RAO for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| RAMANATHAM & RAO | FY 2023 | 002934S |
Shareholding
The shareholding of Daewoong Pharmaceutical (India) Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Daewoong Pharmaceutical (India) Private Limited, buy the company report.
Deals & funding
Daewoong Pharmaceutical (India) Private Limited has 2 deals on record (1 rights issue, 1 funding round), with disclosed funding of ₹2.21 Cr; the latest was in March 2019.
Total deals
2
Rights issue
1
Funding round
1
Disclosed funding
₹2.21 Cr
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2019 | Funding round | ₹2.21 Cr | Investors: Daewoong Pharmaceutical Company Limited |
| Oct 2014 | Rights issue | ₹45.1 Lakh | Investors: Daewoong Pharmaceutical Company Limited |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Daewoong Pharmaceutical (India) Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Daewoong Pharmaceutical (India) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Daewoong Pharmaceutical (India) Private Limited has a workforce of 23 employees on its EPFO records as of Mar 30, 2024, across 1 active EPFO establishment.
Employee count
23
Active EPFO establishments
1
GST
Daewoong Pharmaceutical (India) has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAECD4700D1Z7 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Daewoong Pharmaceutical (India) Private Limited, buy the company report.
Recent activity
Daewoong Pharmaceutical (India) Private Limited has 8 board changes on record since 2016: 3 appointments and 5 cessations. The latest: Neelima Aryasomayajula was appointed as Additional Director on 21 May 2024.
AGM
Daewoong Pharmaceutical (India) Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Daewoong Pharmaceutical (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Appointed
Neelima Aryasomayajula was appointed as Additional Director.
Ceased
Gwan Young Kim ceased to be Additional Director.
Ceased
Yong Hae Han ceased to be Director.
Appointed
Gwan Young Kim was appointed as Director.
Ceased
Chung Hyun Song ceased to be Director.
Ceased
Insuk Oh ceased to be Director.
Ceased
Minsuk Lee ceased to be Director.
Appointed
Chung Hyun Song was appointed as Director.
Incorporation
30 Nov 2012
Daewoong Pharmaceutical (India) Private Limited was registered on 30 Nov 2012 with Roc Hyderabad & aged 13 years 11 months as per MCA records.
News
Frequently asked questions
Daewoong Pharmaceutical (India) is an active foreign private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 30 November 2012 (14+ years old) and is registered under CIN U24232TG2012FTC084511.
Daewoong Pharmaceutical (India) has 3 current directors:
- Neelima Aryasomayajula - Additional Director
- Gwan Young Kim - Director
- Chung Hyun Song - Director
The latest financial statements of Daewoong Pharmaceutical (India) on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Daewoong Pharmaceutical (India) is 36AAECD4700D1Z7, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Daewoong Pharmaceutical (India) is U24232TG2012FTC084511. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Daewoong Pharmaceutical (India) was incorporated on 30 November 2012, making it 14+ years old. It is registered with the Registrar of Companies, Hyderabad.
Daewoong Pharmaceutical (India) has 2 deals on record (1 rights issue, 1 funding round), with disclosed funding of ₹2.21 Cr; the latest was in March 2019.
Neelima Aryasomayajula was appointed as Additional Director on 21 May 2024. Gwan Young Kim ceased to be Additional Director on 21 Sep 2018. Yong Hae Han ceased to be Director on 17 May 2018. Daewoong Pharmaceutical (India) has 8 board changes on record in total.
Yes, Daewoong Pharmaceutical (India) is registered as a small enterprise under Udyam registration (number: UDYAM-TS-20-0012350).
Daewoong Pharmaceutical (India) can be reached through the website daewoong.com. Its registered office is in Hyderabad, Telangana, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages